Device promotion oversight could be placed solely with FTC, advertising group says.
This article was originally published in The Gray Sheet
DEVICE, DRUG PROMOTIONAL ACTIVITIES REGULATION EXCLUSIVELY BY FTC is proposed by the American Association of Advertising Agencies (AAAA) in its legislative proposal to reform FDA's device and drug marketing and communications regulations. Congress "could grant FTC exclusive jurisdiction to regulate marketing of prescription drugs and devices where the FDA and FTC now have concurrent and overlapping jurisdictions," the association says, as "one way to accomplish both substantive and procedural reform."
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.